Cancer-related investigations have long been in
INTRODUCTION
Cancer is a class of diseases in which abnormal cells divide without control and are able to invade other tissues (1) . These diseases are a leading cause of death worldwide, accounting for seven million deaths in 2008 (based on 'World Cancer Report 2008', from the WHO). A promising approach to cancer detection and treatment is based on reliable biomarker discovery, which assesses molecular changes between cancerous and normal tissue. For many years, scientists have been searching for biomarkers to aid in cancer diagnosis, prognosis and therapy (2) . Knowledge of cancer biomarkers has increased greatly with improvements in screening methods, from conventional experiments (e.g. gel electrophoresis and immunohistochemistry) to high-throughput technologies (e.g. microarray, mass spectrometry [MS] and sequencing).
In recent decades, several cancer-related database systems have been developed to associate human genes with cancers. CGED (3) and ITTACA (4) collect cancerrelated gene expression and clinical data. TAG (http:// www.binfo.ncku.edu.tw/TAG/GeneDoc.php, 519genes) and TGDBs (http://www.tumor-gene.org/Breast/index .html, 300genes) provide repositories for cancer-related genes (e.g. oncogenes, tumor suppressor genes). COSMIC (5) stores 78 933 somatic mutation information related to human cancers. All these databases focus on DNA/RNA level changes, such as mutation, single nucleotide polymorphisms (SNPs) and mRNA expression change. Most pathophysiologic changes in cancer, however, are mediated by expression change at the protein level (6) .
In the post-genomic era, proteomics has been developed to quantify protein expression changes. The primary technology of quantitative proteomics is stable isotope labeling combined with liquid chromatography tandem MS (LC-MS/MS) (7), which has been used successfully in lung cancer (8) (9) (10) , breast cancer (11-13), leukemia (14) and other cancer types. For example, Ralhan et al. employed iTRAQ-2DLC-MS/MS to identify potential biomarkers of oral premalignant lesions (OPLs), and the subsequent immunohistochemistry verified that the combination of three best-performing biomarkers achieved a sensitivity of 0.83 and a specificity of 0.74 in discriminating OPLs from normal oral tissues (15) .
With more and more cancer proteomic research being performed, a unifying bioinformatic resource is required to collect and analyze the resulting data. Thus we have developed a manually curated database of differentially expressed proteins in human cancers (dbDEPC). This database integrates results from various MS experiments to provide protein-level expression changes for 1803 proteins in 15 cancers. Compared with previous cancerrelated databases, dbDEPC is a novel resource, in providing information on differentially expressed proteins; thus, it may become an important repository for candidate protein biomarkers. Genomic structure variations also are provided in dbDEPC, to combine information on cancer-related protein-level and DNA-level changes. All data can be searched, browsed and downloaded directly from the website.
DATA COLLECTION
A semi-automatic method was used to curate differentially expressed proteins from peer-reviewed MS-related papers, as follows: Figure 1A illustrates the number of differentially expressed proteins collected for each cancer type. Taking HCC as an example, 647 proteins are differentially expressed, among which 261 proteins are up-regulated and 323 proteins are down-regulated. Another 63 proteins show conflicting expression change (up or down) in different HCC experiments, which might be due to different HCC samples or experimental protocols. dbDEPC provides more informative and reliable data than does a single experiment under such circumstances, showing the advantage of data integration.
We compared the content of dbDEPC with that of two existing cancer-associated gene databases (CGDCP, CGC). Most differentially expressed genes in dbDEPC are newly identified, with only 11% of genes shared with these two external databases ( Figure 1B) . For 106 genes validated by LTP experiments, only 8% overlap with external databases (Figure 1B) . These results indicate that dbDEPC will be an important complement to previous databases.
We also explored whether differentially expressed genes in dbDEPC were associated with genomic variations. As shown in Figure 1C , 99% of dbDEPC genes have known SNPs (dbSNP database) and 41% of genes have known structural variations in the human genome (including copy number variations, inversions and insert-deletions; DGV database). This rate of DNA-level variation is significantly higher than that seen for general human genes, by Fisher's exact test (P < 0.0001). This result may offer a starting point for explaining the mechanism of protein expression change in cancers.
DATABASE UTILITY
dbDEPC provides two types of searching models on its search page (Figure 2A) . One is text search, supporting protein IPI identifier, Entrez gene ID or protein description. Another is sequence similarity search by BLASTP. dbDEPC's browsing function is implemented via the browse page ( Figure 2B ). Users can select one or multiple cancers to browse differentially expressed proteins. Search and browse results list basic information for protein matches ( Figure 2C ), such as IPI ID, description, related cancer and expression change (up or down). More detailed information for each protein can be accessed by clicking the protein ID link, as shown in Figure 2D (and detailed in Supplementary Figure S1 ). Detailed information contains three sections: summary, expression and annotation (Supplementary Figure S1) . The summary section summarizes expression changes seen in different cancers, as well as providing protein description, IDs, molecular weight and isoelectric point. The expression section plots a heatmap to visualize the expression change of proteins in multiple cancers, and provides information about all MS experiments that have identified the protein, including the PMIDs of associated publications, cancer type, expression change G a s t r ic C a n c e r P r o s t a t e C a n c e r C e r v ic a l C a n c e r P a n c r e a t ic C a r c in o m a C o lo r e c t a l C a n c e r O v a r ia n C a n c e r E s o p h a g e a l C a n c e r L u n g A d e n o c a r c in o m a B r e a s t C a n c e r T h y r o id C a n c e r O r a l C a n c e r L e u k e m ia U t e r in e C a n c e r up up or down down O r a l P r e m a li g n a n t L e s io n s (up or down), fold change, MS equipments and so on. If available, validation information (LTP, CGDCP, CGC) also is provided in the expression section. The annotation section contains diverse annotations: SNPs, genomic structure variations, domain organization, Gene Ontology, KEGG pathways and protein sequence. Taking TFRC (IPI00022462.2) as an example (shown in Supplementary Figure S1 ), the summary section briefly describes that TFRC is down-regulated in HCC; the expression section shows that its fold change is 0.236766 or 0.3056256 based on an LTQ-FT MS experiment from an paper with the PMID 1864787, its gene is reported as a cancer-related gene based on the CGDCP database and it has somatic mutations in non-Hodgkin's lymphoma based on the CGC database; and the annotation section notes 15 SNPs, copy number variations and inversion in the gene region, and provides other functional terms.
Finally, dbDEPC's profile page can assist users to investigate differences in protein profile among different cancers. If users input a protein list and select cancers of interest on the profile page ( Figure 3A ) the database will return a heatmap visualizing the expression change of proteins in multiple cancers ( Figure 3B ) and a table listing all differentially expressed proteins. Up-and down-regulation are represented by red and green color, respectively. The color grade is dependent on a 'validation rank', which is calculated based on number of data sources (MS, LTP, CGDCP, CGC). Deeper color denotes more sources that relate the protein with a particular cancer.
DATABASE AVAILABILITY
All data in dbDEPC are freely available for download without password protection for academic users. dbDEPC can be accessed via http://dbdepc.biosino .org/index/, and data can be downloaded through the download page as text files.
DISCUSSION AND CONCLUSION
Differentially expressed proteins in cancers are often regarded as candidate biomarkers for diagnosis, prognosis and prediction of response to therapy. Data in dbDEPC ( Figure 3C) show that some proteins have differential expression in only one cancer (specific proteins), while other proteins have differential expression in multiple cancers (common proteins). For example, the HSPA5 protein (78 kDa glucose-regulated protein, IPI00003362.2) is up-regulated in seven cancers, downregulated in two cancers and shows conflicting experimental results in another cancer. Specific proteins may be candidate diagnostic biomarkers for specific cancers, whereas common proteins could be regarded as biomarkers for a group of cancers. dbDEPC increases the reliability of information on cancer biomarkers by curating proteomics data from multiple experiments. In addition, dbDEPC is the first database to emphasize protein-level expression change in cancers based on high-throughput MSy experiments.
In dbDEPC, the integration of data from multiple cancers also allows for comparison among cancers based on protein expression patterns. Using the expression profiles of 1487 human proteins in 13 cancers (disregarding two cancers with <50 differentially expressed proteins), we obtained a hierarchical clustering by Jaccard similarity coefficient ( Figure 3D ). The associations among some cancers might suggest underlying functional interaction. For example, breast cancer clusters with ovarian cancer and prostate cancer. This may imply that sex-hormonerelated cancers share some common biomarkers. Data resources such as dbDEPC may facilitate development of a more systemic understanding of the relationships among different cancers at the protein expression level.
Moreover, each protein in dbDEPC is annotated with any known variations in its gene, allowing for exploration of possible underlying mechanism for protein expression changes in cancer. In fact, 99% of the genes collected in dbDEPC have known SNPs and 41% have known structural variations in the human genome (including copy number variations, inversions and insert-deletions). Additionally, most differentially expressed genes in dbDEPC are newly identified, with only 11% of genes overlapping with two external databases. In conclusion, dbDEPC is aimed to become an important reference database for differentially expressed proteins in human cancers. This new resource may facilitate cancer research and contribute to biomarker discovery.
FUTURE DEVELOPMENT
With more and more cancer proteomics experiments being performed, we plan to update dbDEPC annually. The current dbDEPC collects primarily human proteins. Model organisms are much easier to study and disease models have contributed significantly to cancer research (24) . Thus, we also plan to add data from mouse and rat. Previously we have established a cancer-related gene expression signature database (under submission). Another important extension in the future will be to explore the association between RNA levels as recorded in the previous database and protein levels in the present database.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
